Straits Times Index
3,332.80 -10.55 (-0.32%) Nikkei
39,583.08 +241.54 (+0.61%) Hang Seng
17,718.61 +2.14 (+0.01%) FTSE 100
8,186.35 +6.67 (+0.08%) Bitcoin USD
60,808.65 -943.05 (-1.53%) CMC Crypto 200
1,270.05 -13.78 (-1.07%)
Indivior PLC (INDVL.XC)
| Previous close | 1,291.00 |
| Open | 1,275.00 |
| Bid | 1,248.00 x N/A |
| Ask | 1,250.00 x N/A |
| Day's range | 1,249.00 - 1,280.50 |
| 52-week range | 1,128.00 - 1,926.00 |
| Volume | |
| Avg. volume | 99,812 |
| Market cap | 1.674B |
| Beta (5Y monthly) | 0.11 |
| PE ratio (TTM) | 41,633.34 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 16 Jun 2016 |
| 1y target est | N/A |
- PR Newswire
Indivior Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (OPVEE 2.7mg) and IN Naloxone (4 mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression and Cardiac Arrest
Indivior PLC (LSE/Nasdaq: INDV) today announced the publication of a modeling study in Frontiers in Psychiatry that predicts OPVEE (nalmefene) nasal spray (2.7 mg nalmefene, equivalent to 3 mg of nalmefene hydrochloride) resulted in larger reductions in the incidence of simulated cardiac arrest following overdose from high doses of potent synthetic opioids, compared to a 4 mg dose of IN naloxone.
- PR Newswire
Indivior Announces Dosing of First Subject with INDV-2000 in a Phase 2 Study Assessing the Safety and Efficacy of INDV-2000 in Individuals with Opioid Use Disorder
Indivior PLC (LSE/Nasdaq: INDV) today announced the dosing of the first subject with INDV-2000 in a Phase 2 double-blind, placebo controlled, randomized, dose-ranging study to assess the safety and efficacy of INDV-2000 over 3 months in treatment-seeking individuals with Opioid Use Disorder (OUD) (NCT06384157). The purpose of this proof-of-concept study is to measure safety and efficacy and to determine the dose-response relationship for INDV-2000 in participants with moderate to severe OUD who
- PR Newswire
Indivior to Host Analyst Teach-in Event in New York City; Reconfirms Full Year 2024 Guidance
Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, announced that in anticipation of the expected primary listing of the Company's shares on Nasdaq , members of Indivior's senior leadership team will be hosting an analyst teach-in event today in New York City. The event, which will be webcast (see details below), is intended to provide an in-depth overview of Indivior's growth and value creation path. During the event, the Company will reconfirm its unchanged FY 2024
